Compared to the expression only cohort, the IHC cohort had a greater proportion of ER+/HER2− breast cancers (68.3% vs. 50.5%) and more patients with normal BMI (57.6% vs. 46.6%). The gene discussed is ESR1; the disease is breast carcinoma.